Why Science? | ICH E7 Geriatric Populations, Pharmacokinetics, Safety and Efficacy

The guidance applies when a medicine is likely to be used substantially in older people. It asks whether efficacy, adverse reactions, pharmacokinetics or dose-response differ from younger adults. The aim is evidence that supports safe and effective use, not a separate development programme merely because patients are older.

The inclusive purpose of e7 studies medicines likely to be used by older adults is to let evidence resemble the people who will depend on it. The guidance applies when a medicine is likely to be used substantially in older people. It asks whether efficacy, adverse reactions, pharmacokinetics or dose-response differ from younger adults. The aim is evidence that supports safe and effective use, not a separate development programme merely because patients are older. Keep this boundary visible: Age alone may be less informative than organ function, frailty, comorbidity or concomitant treatment.

A strong science note separates observation from interpretation. Write the real-world use case and identify which age-related factors could change dose, benefit or harm. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Next chapter

FDA identifies the original E7 guidance as final in August 1994, issued by CDER and CBER. FDA’s final March 2012 E7 questions and answers, under docket FDA-2009-D-0528, clarify the design and conduct of programmes for medicines expected to have significant use among older adults.

For the e7 guidance and q&a are final, age can point to a question but rarely supplies the whole mechanism. FDA identifies the original E7 guidance as final in August 1994, issued by CDER and CBER. FDA’s final March 2012 E7 questions and answers, under docket FDA-2009-D-0528, clarify the design and conduct of programmes for medicines expected to have significant use among older adults. Preserve this guardrail: The Q&A adds current interpretation without erasing the original guidance’s scope.

A strong science note separates observation from interpretation. Create a two-document source receipt with titles, dates, status, docket where shown, offices and purpose. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The development programme should enrol a sufficiently representative geriatric population for the disease and medicine. Numbers and age distribution should support comparisons of safety and efficacy and evaluation of pharmacokinetics when relevant. The needed evidence depends on prevalence, expected use and the questions that could change prescribing.

A useful geriatric analysis of representation should match expected use connects physiology, co-treatment and outcomes. The development programme should enrol a sufficiently representative geriatric population for the disease and medicine. Numbers and age distribution should support comparisons of safety and efficacy and evaluation of pharmacokinetics when relevant. The needed evidence depends on prevalence, expected use and the questions that could change prescribing. The honest limit is: A large overall sample can still be uninformative if older adults are few or unusually healthy.

A strong science note separates observation from interpretation. Compare the trial age distribution and health profile with the intended treatment population. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The original framework commonly uses 65 years and older to describe geriatric participants, but the 2012 Q&A emphasises the full age spectrum. Chronological age can organise reporting; biological mechanisms such as renal function, body composition and frailty explain why response may differ.

The inclusive purpose of chronological age is a practical marker, not a mechanism is to let evidence resemble the people who will depend on it. The original framework commonly uses 65 years and older to describe geriatric participants, but the 2012 Q&A emphasises the full age spectrum. Chronological age can organise reporting; biological mechanisms such as renal function, body composition and frailty explain why response may differ. Keep this boundary visible: A cutoff does not make everyone above it similar or everyone below it low risk.

A strong science note separates observation from interpretation. Report age continuously and in useful bands, then pair it with mechanistic clinical variables. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The Q&A encourages inclusion of patients aged 75 and older because they may carry greater comorbidity, frailty, altered physiology and polypharmacy and are often underrepresented. Enrolment should be adequate to assess whether important differences emerge rather than adding a token handful late in development.

For adults aged 75 and older need visible evidence, age can point to a question but rarely supplies the whole mechanism. The Q&A encourages inclusion of patients aged 75 and older because they may carry greater comorbidity, frailty, altered physiology and polypharmacy and are often underrepresented. Enrolment should be adequate to assess whether important differences emerge rather than adding a token handful late in development. Preserve this guardrail: A subgroup can be clinically important even when its estimate is statistically imprecise.

A strong science note separates observation from interpretation. Set recruitment and retention checks for the oldest intended users and track evidence maturity during the trial. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Excluding people solely because they exceed a fixed age can produce a trial that does not resemble clinical use. Eligibility should be based on justified safety, scientific or operational considerations. Removing unnecessary exclusions lets the programme learn about variability it will face after approval.

A useful geriatric analysis of arbitrary upper age limits can erase relevance connects physiology, co-treatment and outcomes. Excluding people solely because they exceed a fixed age can produce a trial that does not resemble clinical use. Eligibility should be based on justified safety, scientific or operational considerations. Removing unnecessary exclusions lets the programme learn about variability it will face after approval. The honest limit is: Inclusive eligibility still requires safeguards and may not make every trial suitable for every older adult.

A strong science note separates observation from interpretation. Review each exclusion and replace age alone with the specific risk or measurement concern it is meant to address. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Cardiovascular disease, diabetes, cognitive impairment and other conditions can affect endpoints, adverse events and competing risks. Representative enrolment and careful baseline description help readers understand whether outcomes reflect the medicine, underlying illness or their interaction.

The inclusive purpose of comorbidities change baseline risk and treatment response is to let evidence resemble the people who will depend on it. Cardiovascular disease, diabetes, cognitive impairment and other conditions can affect endpoints, adverse events and competing risks. Representative enrolment and careful baseline description help readers understand whether outcomes reflect the medicine, underlying illness or their interaction. Keep this boundary visible: A narrowly selected low-comorbidity sample cannot answer every question about multimorbidity.

A strong science note separates observation from interpretation. Build a causal map connecting comorbidities to exposure, outcome measurement, competing events and follow-up. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Older adults may use several prescribed and non-prescribed products. Enzyme inhibition, altered absorption, additive sedation, bleeding risk or blood-pressure effects can change benefit-risk. E7 connects geriatric evidence with drug-interaction assessment and with documentation of medicines actually taken.

For concomitant medicines create interaction questions, age can point to a question but rarely supplies the whole mechanism. Older adults may use several prescribed and non-prescribed products. Enzyme inhibition, altered absorption, additive sedation, bleeding risk or blood-pressure effects can change benefit-risk. E7 connects geriatric evidence with drug-interaction assessment and with documentation of medicines actually taken. Preserve this guardrail: Counting medicines is not enough; the mechanism, dose, timing and adherence matter.

A strong science note separates observation from interpretation. Create an interaction matrix for common co-treatments and identify which combinations need prospective evidence. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Kidney function often declines with age but varies widely between people. For medicines or active metabolites cleared renally, exposure can rise when clearance falls. Analyses should use measured or estimated renal function and explore its relation to concentration, response and adverse effects rather than treating age as the causal variable.

A useful geriatric analysis of renal function can change exposure connects physiology, co-treatment and outcomes. Kidney function often declines with age but varies widely between people. For medicines or active metabolites cleared renally, exposure can rise when clearance falls. Analyses should use measured or estimated renal function and explore its relation to concentration, response and adverse effects rather than treating age as the causal variable. The honest limit is: An age-based dose rule can misclassify a fit older adult or miss a younger person with impairment.

A strong science note separates observation from interpretation. Plot exposure against renal function and mark the range represented in the trial. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Changes in liver blood flow, metabolic capacity, protein binding, total body water and fat can alter distribution and clearance. Their importance depends on the medicine’s properties and route. Mechanistic understanding helps decide whether dedicated studies, population modelling or monitoring are needed.

The inclusive purpose of hepatic function and body composition also matter is to let evidence resemble the people who will depend on it. Changes in liver blood flow, metabolic capacity, protein binding, total body water and fat can alter distribution and clearance. Their importance depends on the medicine’s properties and route. Mechanistic understanding helps decide whether dedicated studies, population modelling or monitoring are needed. Keep this boundary visible: General age trends cannot predict an individual’s exposure without medicine-specific evidence.

A strong science note separates observation from interpretation. Trace the medicine’s disposition and identify the age-related physiological change most likely to matter. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Older adults may have altered sensitivity to central nervous system, cardiovascular or anticoagulant effects even when concentration is similar. Pharmacodynamic outcomes, functional measures and adverse effects can therefore add information beyond pharmacokinetics. The relevant measure should connect to clinical use.

For pharmacodynamics can change without large pk change, age can point to a question but rarely supplies the whole mechanism. Older adults may have altered sensitivity to central nervous system, cardiovascular or anticoagulant effects even when concentration is similar. Pharmacodynamic outcomes, functional measures and adverse effects can therefore add information beyond pharmacokinetics. The relevant measure should connect to clinical use. Preserve this guardrail: Similar concentration does not prove equal benefit or tolerability.

A strong science note separates observation from interpretation. Compare exposure-response relationships by age and clinical factors rather than concentration alone. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

A useful regimen may depend on renal or hepatic function, interacting medicines, response and tolerability. Trial titration and dose-reduction rules should generate evidence that clinicians can apply. If older adults routinely need a lower starting dose, the reason and escalation path should be explicit.

A useful geriatric analysis of dose selection should integrate organ function and response connects physiology, co-treatment and outcomes. A useful regimen may depend on renal or hepatic function, interacting medicines, response and tolerability. Trial titration and dose-reduction rules should generate evidence that clinicians can apply. If older adults routinely need a lower starting dose, the reason and escalation path should be explicit. The honest limit is: “Start low” is not a substitute for evidence about how to monitor and when to change dose.

A strong science note separates observation from interpretation. Turn dose advice into an if-then algorithm and test it with patients who differ in function and co-treatment. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Falls, confusion, hypotension, bleeding, renal injury or other events may be more consequential in older adults. Analyses should consider incidence, severity, timing, competing events, discontinuation and concomitant therapy. Small counts and multiple subgroup comparisons require cautious interpretation.

The inclusive purpose of safety patterns need event detail and exposure time is to let evidence resemble the people who will depend on it. Falls, confusion, hypotension, bleeding, renal injury or other events may be more consequential in older adults. Analyses should consider incidence, severity, timing, competing events, discontinuation and concomitant therapy. Small counts and multiple subgroup comparisons require cautious interpretation. Keep this boundary visible: A non-significant age interaction does not demonstrate absence of a clinically important risk.

A strong science note separates observation from interpretation. Report absolute events, exposure time, uncertainty and the clinical consequence beside each subgroup comparison. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The medicine should demonstrate benefit in a population that includes the age and health spectrum expected in use. Consistency may support a common effect, while differences may arise from disease severity, adherence, competing risk or altered response. Both effect size and uncertainty matter.

For efficacy should be assessed in relevant older adults, age can point to a question but rarely supplies the whole mechanism. The medicine should demonstrate benefit in a population that includes the age and health spectrum expected in use. Consistency may support a common effect, while differences may arise from disease severity, adherence, competing risk or altered response. Both effect size and uncertainty matter. Preserve this guardrail: An overall positive trial does not reveal whether the oldest or most complex participants benefited similarly.

A strong science note separates observation from interpretation. Place subgroup estimates beside the overall result and investigate mechanisms before declaring consistency or difference. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Transport, sensory impairment, fatigue, cognitive burden and caregiver needs can affect recruitment and follow-up. Flexible visits, accessible materials and proportionate procedures can improve participation without changing the scientific question. Differential dropout should be measured because it can make the retained group unrepresentatively healthy.

A useful geriatric analysis of retention and accessible participation protect validity connects physiology, co-treatment and outcomes. Transport, sensory impairment, fatigue, cognitive burden and caregiver needs can affect recruitment and follow-up. Flexible visits, accessible materials and proportionate procedures can improve participation without changing the scientific question. Differential dropout should be measured because it can make the retained group unrepresentatively healthy. The honest limit is: Convenience adaptations must preserve endpoint meaning, data quality and consent protections.

A strong science note separates observation from interpretation. Audit every visit for burden and name an accessible alternative with equivalent measurement. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Prespecified summaries can examine age bands and continuous age alongside sex, renal function, comorbidity, frailty and co-treatment. Multivariable and exposure-response approaches may help separate correlated factors, but sparse data limit certainty. Exploratory signals should be labelled and followed rather than converted into confident rules.

The inclusive purpose of analysis should examine age with related factors is to let evidence resemble the people who will depend on it. Prespecified summaries can examine age bands and continuous age alongside sex, renal function, comorbidity, frailty and co-treatment. Multivariable and exposure-response approaches may help separate correlated factors, but sparse data limit certainty. Exploratory signals should be labelled and followed rather than converted into confident rules. Keep this boundary visible: Model adjustment cannot create information for people who were never enrolled.

A strong science note separates observation from interpretation. Create an analysis matrix linking each clinical question to variables, sample coverage and decision impact. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The receipt records expected older use, age distribution including over 75, comorbidities, frailty measures, organ function, concomitant medicines, PK, PD, dose changes, efficacy, safety, retention, subgroup uncertainty and label implications. It makes underrepresentation and remaining questions visible.

For a complete e7 receipt makes geriatric evidence usable, age can point to a question but rarely supplies the whole mechanism. The receipt records expected older use, age distribution including over 75, comorbidities, frailty measures, organ function, concomitant medicines, PK, PD, dose changes, efficacy, safety, retention, subgroup uncertainty and label implications. It makes underrepresentation and remaining questions visible. Preserve this guardrail: A polished receipt cannot compensate for an enrolled population that excludes intended users.

A strong science note separates observation from interpretation. Give the receipt to a clinician and ask whether it supports a dose and monitoring decision for three different older adults. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter